COMPANY
Third Arc Bio
Raises and deals from press releases
- Raise Series A · $52M · announced Feb 4, 2026 Company release ↗
Source quote
- Feb 4, 2026 · Company release ↗
“$52M equity adds to previously announced $165M Series A New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn.”
- Feb 4, 2026 · Company release ↗
Timeline
Upcoming milestones
- May 1, 2028 (ESTIMATED) · Phase 1 · ARC101 in Advanced Solid Tumors · NCT06672185
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06672185 | ARC101 in Advanced Solid Tumors | Phase 1 | Recruiting | Feb 5, 2025 | May 1, 2028 (estimated) |